Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Knight Therapeutics Inc. (T:GUD)

Business Focus: Proprietary & Advanced Pharmaceuticals

INK Edge Outlook

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for GUD within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Mar 28, 2024 11:03 ET
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity
Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2024 Report on Business magazine’s fifth annual Women Lead Here list. This annual editorial benchmark identifies...
Read full article
Mar 21, 2024 07:30 ET
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2023. All currency amounts are in...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.49
--
--
Price to Sales - TTM
1.68
1.68
3.46
Price to Book - most recent quarter
0.74
0.74
2.02
Price to Cash Flow per share - TTM
16.40
16.40
9.70
Price to Free Cash Flow per share - TTM
21.18
21.18
12.33
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 15, 20243,232,095-36,911
Feb 29, 20243,269,006-90,574
Feb 15, 20243,359,580-39,767
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.

See business summary

 

Twitter

Search (past week) for $GUD.CA

  • No tweets found